plaque psoriasis
-
Aurobindo’s subsidiary CuraTeQ obtains exclusive rights for BioFactura’s Ustekinumab biosimilar
CuraTeQ has been granted exclusive license rights to commercialize BFI-751 in all major regulated markets including the US, the EU,…
Read More » -
Sun Pharma announces initiation of Phase 2 clinical trial of SCD-044
The study in patients with moderate to severe plaque psoriasis will enrol approximately 240 subjects and topline results are expected…
Read More »